[go: up one dir, main page]

EP2983791A4 - METHODS AND COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE DISEASES - Google Patents

METHODS AND COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE DISEASES

Info

Publication number
EP2983791A4
EP2983791A4 EP14782473.4A EP14782473A EP2983791A4 EP 2983791 A4 EP2983791 A4 EP 2983791A4 EP 14782473 A EP14782473 A EP 14782473A EP 2983791 A4 EP2983791 A4 EP 2983791A4
Authority
EP
European Patent Office
Prior art keywords
compositions
treatment
methods
autoimmune diseases
autoimmune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP14782473.4A
Other languages
German (de)
French (fr)
Other versions
EP2983791A1 (en
Inventor
Francisco J Quintana
Ivan D Mascanfroni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc filed Critical Brigham and Womens Hospital Inc
Publication of EP2983791A1 publication Critical patent/EP2983791A1/en
Publication of EP2983791A4 publication Critical patent/EP2983791A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0008Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/10Cellular immunotherapy characterised by the cell type used
    • A61K40/19Dendritic cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/20Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22Immunosuppressive or immunotolerising
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/20Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24Antigen-presenting cells [APC]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/40Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41Vertebrate antigens
    • A61K40/416Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/33Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y306/00Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/01Hydrolases acting on acid anhydrides (3.6) in phosphorus-containing anhydrides (3.6.1)
    • C12Y306/01005Apyrase (3.6.1.5), i.e. ATP diphosphohydrolase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
EP14782473.4A 2013-04-11 2014-04-11 METHODS AND COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE DISEASES Withdrawn EP2983791A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361853745P 2013-04-11 2013-04-11
PCT/US2014/033872 WO2014169255A1 (en) 2013-04-11 2014-04-11 Methods and compositions of treating autoimmune diseases

Publications (2)

Publication Number Publication Date
EP2983791A1 EP2983791A1 (en) 2016-02-17
EP2983791A4 true EP2983791A4 (en) 2016-11-09

Family

ID=51690049

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14782473.4A Withdrawn EP2983791A4 (en) 2013-04-11 2014-04-11 METHODS AND COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE DISEASES

Country Status (6)

Country Link
US (2) US10426794B2 (en)
EP (1) EP2983791A4 (en)
CN (1) CN105307725B (en)
BR (1) BR112015026019A2 (en)
CA (1) CA2918196A1 (en)
WO (1) WO2014169255A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
CN108129554A (en) 2010-08-10 2018-06-08 洛桑聚合联合学院 Erythrocyte binding therapeutic agent
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
SG10202010936RA (en) 2014-02-21 2020-12-30 Ecole Polytecnique Fed De Lausanne Epfl Epfl Tto Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
WO2017042816A1 (en) 2015-09-10 2017-03-16 Yeda Research And Development Co. Ltd. Ablation of perforin positive dendritic cells in cancer treatment
EP3416624B8 (en) 2016-02-18 2023-08-23 Cour Pharmaceuticals Development Company Inc. Process for the preparation of tolerizing immune-modulating particles
WO2017220989A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 and il-2 cytokines
WO2018065622A1 (en) 2016-10-07 2018-04-12 Secarna Pharmaceuticals Gmbh & Co Kg Immunosuppression-reverting oligonucleotides inhibiting the expression of cd39
EP3638296A1 (en) 2017-06-16 2020-04-22 The University Of Chicago Compositions and methods for inducing immune tolerance
CN112384204B (en) 2018-02-26 2023-03-14 安托瑞斯公司 Tolerogenic liposomes and methods of use thereof
CN112384239A (en) 2018-05-09 2021-02-19 芝加哥大学 Compositions and methods for affecting immune tolerance
WO2019236593A1 (en) * 2018-06-05 2019-12-12 The Trustees Of The University Of Pennsylvania Compositions and methods of muscle specific kinase chimeric autoantibody receptor cells
US20230399376A1 (en) * 2019-05-27 2023-12-14 Baker Heart and Diabetes Institute Binding proteins comprising the extracellular domain of cd39 and methods of treating or preventing neurological diseases
EP4359084A4 (en) * 2021-06-22 2025-10-08 Univ Columbia NEW mRNA VACCINE FOR AUTOIMMUNITY
CN114931633B (en) * 2022-06-10 2025-07-04 苏州尔生生物医药有限公司 Preparation method and application of autoimmune disease vaccine derived from pre-activated antigen presenting cells
CN120192922A (en) * 2025-05-26 2025-06-24 华中科技大学同济医学院附属同济医院 In vitro induced tolerant dendritic cells and preparation method and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006066088A2 (en) * 2004-12-16 2006-06-22 Genentech, Inc. Methods for treating autoimmune disorders
WO2010072797A1 (en) * 2008-12-22 2010-07-01 The Provost, Fellows and Scholars of The Holy and Undivided Trinity of Queen Elizabeth, Near Dublin Compounds and methods for the treatment of autoimmune and inflammatory disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004060291A2 (en) * 2002-12-31 2004-07-22 Schering Corporation Uses of mammalian cytokine; related reagents
WO2008024299A2 (en) 2006-08-21 2008-02-28 Synta Pharmaceuticals Corp. Combination with bis(thiohydrazide amides) for treating cancer
CA2671697A1 (en) * 2006-12-07 2008-06-12 Schering Corporation Use of il-27 agonists to reduce immune mediated abortion
EP2591804A3 (en) 2007-09-24 2014-04-16 Bar-Ilan University Polymer nanoparticles coated by magnetic metal oxide and uses thereof
JP2011503104A (en) * 2007-11-09 2011-01-27 カリフォルニア インスティテュート オブ テクノロジー Immunomodulatory compounds and related compositions and methods
MX340972B (en) * 2008-10-08 2016-08-02 Intrexon Corp CELLS MANIPULATED BY ENGINEERING THAT EXPRESS MULTIPLE IMMUNOMODULATORS, AND USE OF THE SAME.
EP2413958A4 (en) 2009-03-31 2014-04-02 Univ East Carolina CYTOKINES AND NEUROANTIGENES FOR THE TREATMENT OF IMMUNE DISEASES
AU2011268146A1 (en) * 2010-06-17 2013-01-10 Actogenix Nv Compositions and methods for treating inflammatory conditions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006066088A2 (en) * 2004-12-16 2006-06-22 Genentech, Inc. Methods for treating autoimmune disorders
WO2010072797A1 (en) * 2008-12-22 2010-07-01 The Provost, Fellows and Scholars of The Holy and Undivided Trinity of Queen Elizabeth, Near Dublin Compounds and methods for the treatment of autoimmune and inflammatory disease

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
B. M. MATTA ET AL: "IL-27 Production and STAT3-Dependent Upregulation of B7-H1 Mediate Immune Regulatory Functions of Liver Plasmacytoid Dendritic Cells", THE JOURNAL OF IMMUNOLOGY, vol. 188, no. 11, 16 April 2012 (2012-04-16), US, pages 5227 - 5237, XP055306344, ISSN: 0022-1767, DOI: 10.4049/jimmunol.1103382 *
D. C. FITZGERALD ET AL: "Suppressive Effect of IL-27 on Encephalitogenic Th17 Cells and the Effector Phase of Experimental Autoimmune Encephalomyelitis", THE JOURNAL OF IMMUNOLOGY, vol. 179, no. 5, 20 August 2007 (2007-08-20), US, pages 3268 - 3275, XP055306398, ISSN: 0022-1767, DOI: 10.4049/jimmunol.179.5.3268 *
IVAN D MASCANFRONI ET AL: "IL-27 acts on DCs to suppress the T cell response and autoimmunity by inducing expression of the immunoregulatory molecule CD39", NATURE IMMUNOLOGY, vol. 14, no. 10, 1 September 2013 (2013-09-01), GB, pages 1054 - 1063, XP055306298, ISSN: 1529-2908, DOI: 10.1038/ni.2695 *
IVAN D MASCANFRONI ET AL: "New Pieces in the Puzzle How Does Interferon-? Really Work in Multiple Sclerosis?", ANNALS OF NEUROLOGY, vol. 65, no. 5, 1 May 2009 (2009-05-01), pages 487 - 488, XP055306333 *
See also references of WO2014169255A1 *

Also Published As

Publication number Publication date
US20200069731A1 (en) 2020-03-05
US10426794B2 (en) 2019-10-01
CN105307725A (en) 2016-02-03
WO2014169255A1 (en) 2014-10-16
CA2918196A1 (en) 2014-10-16
EP2983791A1 (en) 2016-02-17
US20160058792A1 (en) 2016-03-03
BR112015026019A2 (en) 2017-07-25
CN105307725B (en) 2020-06-16

Similar Documents

Publication Publication Date Title
FR22C1011I2 (en) PRODRUGS OF FUMARATES AND THEIR USE FOR THE TREATMENT OF VARIOUS DISEASES
EP2983791A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
EP3448875A4 (en) COMPOSITIONS FOR THE TREATMENT OF DISEASES
EP3370703A4 (en) COMBINATION OF GEMCABEN FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
EP3389672A4 (en) COMPOSITIONS AND METHODS FOR TREATING HEPATIC DISEASES
MA43283A (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
EP3390634A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR DISEASES
EP2872151A4 (en) ACELLULAR PRO-TOLEROGENIC COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES
EP3341391A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF PAIN
EP2953950A4 (en) COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES
EP2968133A4 (en) TOPICAL COMPOSITIONS AND METHODS OF TREATING TOPICAL DISORDERS
EP2800579A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF DIABETES
EP2967062A4 (en) DEETHYLHYDROXYCHLOROQUINE FOR THE TREATMENT OF DISEASES ASSOCIATED WITH INFLAMMATION
EP2741771A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES
EP3316887A4 (en) GLS1 INHIBITORS FOR THE TREATMENT OF DISEASES
EP2922534A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
FR3017298B1 (en) CONJUGATES AND PRO-DRUGS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES
EP3344258A4 (en) TREATMENT OF AUTOIMMUNE DISEASES AND SELF-INFLAMMATORY DISEASES
EP2968478A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF CARBOXYHEMOGLOBINEMIA
EP2879620A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF BONE EMIDIES AND OPEN FRACTURES
EP2830644A4 (en) METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF NEUROPATHY
EP3395341A4 (en) COMPOSITION FOR THE TREATMENT OF NEUROMITRIC DISEASES AND USE THEREOF
EP2544686A4 (en) COMBINED METHODS FOR THE TREATMENT OF DISEASES
EP2968435A4 (en) PEPTIDES FOR THE TREATMENT OF AUTOIMMUNE DISEASES
EP2863939A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF VITILIGO

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20151111

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIN1 Information on inventor provided before grant (corrected)

Inventor name: QUINTANA, FRANCISCO J.

Inventor name: MASCANFRONI, IVAN D.

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20161010

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 37/06 20060101AFI20161004BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20180305

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20221101